Anti-ceruloplasmin antibodies and uses thereof
AssigneeAlexion Pharmaceuticals, Inc.
InventorsDavid George Potter, Jennifer Ann Dzielawa, Brenda Sue Carter, Mark Ma
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies which bind to ceruloplasmin and are useful for various applications, including detecting ceruloplasmin and immunocapturing ceruloplasmin in biological samples. The antibodies are useful in methods of measuring non-ceruloplasmin-bound copper concentrations and labile-bound copper concentrations in biological samples.
Claims20
An isolated antibody which binds to human ceruloplasmin having the amino acid sequence set out in SEQ ID NO:
- 1, comprising:
- (a) heavy chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 5, 6, and 7, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 8, 9, and 10, respectively;
- (b) heavy chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 29, 30, and 31, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 32, 33, and 34, respectively;
- or
- (c) heavy chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 53, 54, and 55, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 56, 57, and 58, respectively.
An antibody mixture comprising two or three antibodies which bind to human ceruloplasmin having the amino acid sequence set out in SEQ ID NO:
- 1, wherein the two or three antibodies are selected from the group consisting of:
- (a) an isolated antibody comprising heavy chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 5, 6, and 7, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 8, 9, and 10, respectively;
- (b) an isolated antibody heavy chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 29, 30, and 31, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 32, 33, and 34, respectively;
- and
- (c) an isolated antibody heavy chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 53, 54, and 55, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
- 56, 57, and 58, respectively.
Dependencies are inferred from the claim text.